U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H28N4O2
Molecular Weight 404.5047
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of APP-CHMINACA

SMILES

NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NN(CC3CCCCC3)C4=CC=CC=C24

InChI

InChIKey=DMHWDSGURMXMGE-FQEVSTJZSA-N
InChI=1S/C24H28N4O2/c25-23(29)20(15-17-9-3-1-4-10-17)26-24(30)22-19-13-7-8-14-21(19)28(27-22)16-18-11-5-2-6-12-18/h1,3-4,7-10,13-14,18,20H,2,5-6,11-12,15-16H2,(H2,25,29)(H,26,30)/t20-/m0/s1

HIDE SMILES / InChI

Approval Year

Name Type Language
APP-CHMINACA
Common Name English
1H-INDAZOLE-3-CARBOXAMIDE, N-((1S)-2-AMINO-2-OXO-1-(PHENYLMETHYL)ETHYL)-1-(CYCLOHEXYLMETHYL)-
Systematic Name English
APP-CHMINACA-
Common Name English
APP-CHMINACA RM
Common Name English
PX-3-
Common Name English
N-(2-AMINO-1-BENZYL-2-OXO-ETHYL)-1-(CYCLOHEXYLMETHYL)INDAZOLE-3-CARBOXAMIDE
Systematic Name English
Code System Code Type Description
CAS
1185887-14-2
Created by admin on Sat Dec 16 11:45:12 GMT 2023 , Edited by admin on Sat Dec 16 11:45:12 GMT 2023
PRIMARY
FDA UNII
3877T06H05
Created by admin on Sat Dec 16 11:45:12 GMT 2023 , Edited by admin on Sat Dec 16 11:45:12 GMT 2023
PRIMARY
MANUFACTURER PRODUCT INFORMATION
APP-CHMINACA RM
Created by admin on Sat Dec 16 11:45:12 GMT 2023 , Edited by admin on Sat Dec 16 11:45:12 GMT 2023
PRIMARY AB-CHMINACA (Item No. 15434) in a synthetic cannabinoid (CB) featuring a 1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (CHMINACA) base. It displays a 10-fold greater affinity for the central CB1 receptor (Ki = 0.9 nM) than that of JWH 018 (Item No. 10900).1,2 APP-CHMINACA is a derivative of AB-CHMINACA. The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.
WIKIPEDIA
PX-3
Created by admin on Sat Dec 16 11:45:12 GMT 2023 , Edited by admin on Sat Dec 16 11:45:12 GMT 2023
PRIMARY PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication. The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1 (5F-APP-PICA, SRF-30), PX-2 (5F-APP-PINACA, FU-PX) and APP-FUBINACA were reported by the EMCDDA in late 2014. Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015.
EPA CompTox
DTXSID201009998
Created by admin on Sat Dec 16 11:45:12 GMT 2023 , Edited by admin on Sat Dec 16 11:45:12 GMT 2023
PRIMARY
PUBCHEM
44206137
Created by admin on Sat Dec 16 11:45:12 GMT 2023 , Edited by admin on Sat Dec 16 11:45:12 GMT 2023
PRIMARY